Chronic obstructive pulmonary disease Study Guide

📖 Core Concepts Chronic Obstructive Pulmonary Disease (COPD) – a progressive, irreversible airflow limitation caused by small‑airway disease and/or emphysema. Airflow limitation is defined by a post‑bronchodilator FEV₁/FVC < 0.70. Phenotypes – observable disease patterns (e.g., emphysema‑dominant “pink puffer”, chronic‑bronchitis‑dominant “blue bloater”, frequent‑exacerbator, asthma‑COPD overlap, pulmonary‑vascular). Endotypes – underlying biological mechanisms (neutrophil‑centric T2‑low vs. eosinophil‑centric T2‑high). Exacerbation – acute worsening lasting days‑to‑weeks, commonly triggered by viral or bacterial infection or irritants. Key risk factors – tobacco smoking (primary), biomass fuel, air pollution, occupational dusts, alpha‑1 antitrypsin deficiency, early‑life lung insults, asthma, airway hyper‑responsiveness. 📌 Must Remember Spirometry diagnostic cut‑off: FEV₁/FVC < 0.70 after bronchodilator. Smoking cessation is the single most effective intervention to slow progression. Frequent exacerbator: ≥2 exacerbations/yr → faster FEV₁ decline, poorer prognosis. Inhaled corticosteroids (ICS) are indicated mainly for eosinophilic (T2‑high) endotype or ≥2 exacerbations/yr; they raise pneumonia risk. Long‑term oxygen therapy (LTOT) indication: PaO₂ ≤ 55 mm Hg (or ≤ 60 mm Hg with cor pulmonale) → target SatO₂ 88‑92 %. Triple therapy (LABA + LAMA + ICS) reserved for high eosinophil counts or frequent exacerbations; monitor for pneumonia. Alpha‑1 antitrypsin deficiency → early‑onset emphysema; treat with IV augmentation. BODE index (BMI, Obstruction, Dyspnea, Exercise) predicts mortality but should be used with exacerbation/frailty data. 🔄 Key Processes Diagnosis Workflow Identify at‑risk patient (≥35 yr, dyspnea, chronic cough, exposure). → Perform post‑bronchodilator spirometry. If FEV₁/FVC < 0.70, stage severity by % predicted FEV₁. Assess symptom burden (CAT, MRC dyspnea scale) and exacerbation history → assign GOLD A‑D group. Exacerbation Management Step 1: Increase short‑acting bronchodilators (SABA + SAMA). Step 2: Add oral corticosteroid (5‑day course). Step 3: If purulent sputum → start appropriate antibiotic (e.g., macrolide). Step 4: Provide supplemental O₂, titrate to 88‑92 % SatO₂; avoid hyperoxia. Pharmacologic Maintenance Escalation Mild symptoms: LABA or LAMA. Moderate/Severe: LABA + LAMA. Frequent exacerbations + eosinophilia: Add ICS → triple therapy. Chronic bronchitis with systemic steroids: Consider roflumilast (PDE‑4 inhibitor). 🔍 Key Comparisons Emphysema‑dominant (“pink puffer”) vs. Chronic bronchitis‑dominant (“blue bloater”) Emphysema: loss of alveolar walls → barrel chest, weight loss, pursed‑lip breathing. Bronchitis: mucus hypersecretion → cyanosis, productive cough, overweight. Short‑acting β₂‑agonist (SABA) vs. Short‑acting muscarinic antagonist (SAMA) SABA: rapid bronchodilation, 4‑6 h duration. SAMA: blocks vagal tone, useful in combination for additive relief. Inhaled corticosteroid (ICS) vs. Phosphodiesterase‑4 inhibitor (Roflumilast) ICS: anti‑inflammatory, best for eosinophilic phenotype; ↑ pneumonia risk. Roflumilast: oral, anti‑inflammatory for chronic bronchitis; ↓ weight, may worsen depression. ⚠️ Common Misunderstandings “COPD is reversible” – airflow limitation is only partially reversible; bronchodilators improve symptoms but do not normalize spirometry. “All smokers develop COPD” – only 20 % of smokers develop clinically significant disease; genetics, exposure intensity, and gender modulate risk. “A normal FEV₁ rules out COPD” – early small‑airway disease may show reduced FEF₂₅‑₇₅ before FEV₁ falls; consider risk factors and symptoms. “ICS are always beneficial” – in neutrophil‑centric (T2‑low) COPD they add little benefit and increase pneumonia risk. 🧠 Mental Models / Intuition “Airflow = Pipe + Sponge” – think of the airway as a pipe (small‑airway narrowing) and the alveolar “sponge” (emphysema). The more the pipe is narrowed and the sponge is destroyed, the worse the airflow limitation. “Exacerbation cascade” – infection → ↑ inflammation → ↑ mucus & airway edema → air‑trapping → hypoxemia → possible hypercapnia. Breaking the cascade early (bronchodilators + steroids + antibiotics) prevents progression. “Risk factor layering” – each additional exposure (smoking + pollution + occupational dust) adds a “layer” of injury; the cumulative load predicts earlier onset and faster decline. 🚩 Exceptions & Edge Cases Fixed FEV₁/FVC ratio over‑diagnoses in the elderly – consider age‑adjusted lower limits or confirm with symptom profile. Alpha‑1 antitrypsin deficiency – may present with severe emphysema in < 40 yr non‑smokers; requires specific testing regardless of smoking history. Chronic bronchitis with normal spirometry – not classified as COPD but signals increased future risk; monitor and encourage smoking cessation. Beta‑blockers – not contraindicated; cardio‑selective agents can be used when indicated for heart disease. 📍 When to Use Which First‑line maintenance – LABA + LAMA for most symptomatic patients (GOLD B‑D). Add ICS – if eosinophils ≥300 cells/µL or ≥2 exacerbations/yr despite LABA + LAMA. Roflumilast – chronic bronchitis phenotype with frequent exacerbations and inability to tolerate higher‑dose steroids. LTOT – resting PaO₂ ≤ 55 mm Hg (or ≤ 60 mm Hg with cor pulmonale). Pulmonary rehabilitation – all patients with mMRC ≥ 2 or CAT ≥ 10, especially after an exacerbation. 👀 Patterns to Recognize Tripod posture + pursed‑lip breathing → advanced COPD with air‑trapping. Productive cough ≥3 months/yr for 2 yr → chronic bronchitis component. Frequent winter colds + rapid symptom escalation → viral‑triggered exacerbation. Weight loss + muscle wasting → systemic inflammation, possible cachexia. Elevated eosinophil count + recurrent exacerbations → likely benefit from ICS/biologic therapies. 🗂️ Exam Traps “ICS are first‑line for all COPD” – they are reserved for eosinophilic or frequent‑exacerbator phenotypes; otherwise they increase pneumonia risk. “A fixed FEV₁/FVC < 0.70 in any older adult equals COPD” – may be age‑related decline; verify symptoms and exposure. “All patients need long‑term oxygen” – only those with severe resting hypoxemia meet criteria; over‑prescribing can cause hypercapnia. “Bronchodilator response rules out COPD” – COPD may show some reversibility; lack of full reversal distinguishes it from asthma. “Alpha‑1 antitrypsin deficiency only occurs in smokers” – it can cause early emphysema even in never‑smokers; testing is recommended for all diagnosed COPD patients.